Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Anticoagulants may have advantage over aspirin for low-risk TAVR

Key clinical point: Anticoagulants may be preferable to antiplatelet therapy for preventing leaflet thrombosis in low-risk transcatheter aortic valve replacement.

Major finding: At 30 days, leaflet thrombosis, a feared threat to valve longevity, was less common (4.7% vs. 16.3%; P = .07) on anticoagulation.

Data Source: A prospective randomized trial.

Disclosures: Dr. Rogers reported financial relationships with Edwards Lifesciences and Medtronic.

Citation:

Rogers T et al. CRT 2020.